HALIFAX, Nova Scotia, July 30, 2018 /PRNewswire/ -- ABK Biomedical, Inc., a company dedicated to the research, development and commercialization of innovative embolic therapies, has announced the appointment of Michael J. Mangano as president and chief executive officer. Mangano will be responsible for leading global business activities, including the rapid development, regulatory approval and commercialization of ABK's unique medical device technologies.
Mangano most recently served as president and CEO of ReShape Medical, a U.S. venture-backed company focused on obesity where he increased organizational value and played a lead role in orchestrating the sale of the company to EnteroMedics in October 2017. Prior to ReShape, Mangano was president of the Americas for Sirtex Medical, a leading publicly traded Australian biomedical company, where he grew the business nearly five-fold from $30M to more than $140 million while building a team of 17 to more than 130 employees in a period of six years. His leadership resulted in a dramatic increase in the company's valuation, leading to the recently announced acquisition in progress of Sirtex Medical by CDH Investments for $1.4B USD. Prior to Sirtex, Mangano spent 15 years with Boston Scientific in numerous senior management roles, including overseas assignments in Japan and Australia. Mangano was recently appointed to Board of Directors of Ellex Medical Lasers Limited (ASX:ELX), a global leader in medical devices for the diagnosis and treatment of eye diseases.
ABK Biomedical Chairman of the Board Dr. Aaron Berez commented, "Mike is an accomplished leader with a history of global success in building dynamic teams, leading organizational change, creating and shaping strategies and executing programs – all directly increasing shareholder value. His vast experience in sales and marketing management, product development, strategic planning, international business, M&A, project management and business model development will be invaluable as he takes the reins at ABK and leads the company into the next phase of our evolution."
Mangano will continue to serve on the ABK board of directors.
"I am excited to join the team at ABK, which has outstanding experience in the medical device industry. The talent at ABK, coupled with an innovative technology platform and pipeline, provide a strong foundation and solid prospects for our future growth and success," said Mangano. "I especially look forward to working with the interventional radiology and oncology communities to develop and market novel technologies that will help patients and physicians, and want to thank the founders and the board of ABK for their support."
Dr. Bob Abraham, co-founder and former CEO, is a practicing interventional radiologist and will remain with the company as Chief Medical Officer. He will continue to play a key role in product development and the clinical evolution of ABK's key technology platforms.
About ABK Biomedical, Inc.
ABK Biomedical is organized to research, develop and commercialize breakthrough medical device therapies to improve treatment outcomes and the lives of patients with benign and malignant hypervascular tumors. Specifically, ABK holds intellectual property in the focus area of inorganic polymer microspheres, targeted at the growing field of embolotherapy within the Interventional Radiology/Interventional Oncology medical disciplines. The company possesses advanced intellectual capital, and its own R&D and manufacturing facilities for developing and commercializing unique, breakthrough embolotherapy products.
SOURCE ABK Biomedical, Inc.
ABK Biomedical has received support from the Atlantic Canada Opportunities Agency (ACOA) to commercialize its Easi-Vue embolization microspheres in-house. The successful commercialization of this innovation will lead to new business opportunities and more well-paying jobs as the microspheres are set to compete in global markets. The funding was announced on Thursday February 22 2018 at ABK Biomedical's new facility by Darrell Samson, Member of Parliament for Sackville-Preston-Chezzetcook, on behalf of the Honourable Navdeep Bains, Minister of Innovation, Science and Economic Development and Minister responsible for the Atlantic Canada Opportunities Agency (ACOA).
The contribution, being made through ACOA’s Atlantic Innovation Fund (AIF), is going towards the design and development of custom equipment as well as getting the regulatory approval needed for ABK Biomedical to scale-up its manufacturing process. It will support the manufacturing of devices in a clinical study, enabling regulatory approvals for sale of the device in the United States and globally. This AIF project will create six good quality jobs with the potential for more as demand for the product grows.
“Innovation isn’t just about finding solutions that make our lives better; it’s about improving everyone’s quality of life. That is why the Government of Canada is committed to supporting projects such as this one, which will have an international impact while enhancing Atlantic Canada’s ability to compete in the global marketplace.”
- The Honourable Navdeep Bains, Minister of Innovation, Science and Economic Development and Minister responsible for ACOA
“ABK Biomedical is one of the firms keeping Atlantic Canada’s life sciences community on the leading-edge. By keeping the manufacturing local, ABK will create new jobs and economic opportunities in the area, while setting itself up for international export. Today’s announcement will secure the commercialization of the microspheres to help cancer patients worldwide.”
- Darrell Samson, Member of Parliament for Sackville-Preston-Chezzetcook
“This investment enhances our competitive presence by allowing us to accelerate plans to manufacture and export medical devices internationally directly from Halifax. ABK is now positioned to develop and sustain high quality jobs in the medical device sector in Atlantic Canada and our company and products will soon help improve the lives of patients with hyper vascular tumours globally.”
- Dr. Bob Abraham, CEO, ABK Biomedical Inc.
See ACOA for more news and further news as reported by The Chronicle Herald.
The Society of Interventional Radiology (SIR) 2017 annual meeting will be held in Washington, D.C. At the meeting, experts will present information about interventional oncology and peripheral vascular, venous and neurovascular disease. Join ABK Biomedical as they present their studies entitled "Multi-modal "imageable" embolic microspheres: A preliminary study on occlusion effectiveness, level of occlusion and arterial distribution in a swine liver model” at the Walter E. Washington Convention Centre during the scientific session in Room 143C on March 5th from 3.00PM to 4.30PM. See http://www.sirmeeting.org for more details.
ABKs CEO Dr. Bob Abraham, spoke with Interventional Oncology 360 at the 2016 Annual Scientific Meeting of the Society of Interventional Radiology about our study of imageable embolic microspheres (IEMs) in a swine renal artery embolization model.
Read the full story here.
SIR2016 - 41st Annual Scientific Society of Interventional Radiology Meeting April 2 - 7, Vancouver, British Columbia, Canada
No other meeting offers the diversity of topics, the range of learning environments, the unparalleled access to expert faculty and leading thinkers in the specialty. Join ABK Biomedical on April 5th from 3.00PM to 4.30PM as they present their scientific abstract "A Bilateral Partial Swine Renal Artery Embolization Study using “Imageable” Embolic Microspheres: Assessment of Mechanism of Occlusion, Embolization Effectiveness, Device Migration and Safety” at the Vancouver Convention Centre during the scientific session. See http://www.sirmeeting.org for more details.
CIRSE2015 - 30th Annual Interventional Radiology Congress September 26 - 30, Lisbon, Portugal
For CIRSE 2015, the programme has been designed around six main themes, including, vascular Interventions, transcatheter embolisation, interventional oncology, neurointerventions, non-vascular interventions and IR management. Join ABK on Monday, September 28th, as they present a featured paper at the Centro de Congressos de Lisboa.
See http://www.cirse.org for more details.
SIR2015 - 40th Annual Scientific Society of Interventional Radiology Meeting February 28 - March 5, Atlanta, Georgia, US
The excitement and promise of IR are in the spotlight at SIR 2015. SIR's Annual Scientific Meeting is the world’s largest and most comprehensive IR educational experience designed for all professional levels and all practice environments. http://www.sirmeeting.org
Dynamic Halifax startup ABK Biomedical has engaged Enginuity to deliver engineering support for their ancillary delivery device for OccluRad. ABK are pioneering the use of radio-opaque embolic microspheres in the targeted treatment of tumors. Following early design in Ireland, ABK have brought core engineering to Halifax, in order to advance the device to production.
“Having access to unique creative engineering on our doorstep is key to meeting our investor expectations and delivering on our key business milestones” says Daniel Boyd, Chief Scientific Officer at ABK, adding “proximity is critical to rapid iteration, that’s what ABK needs as we move to the next phase.”
Enginuity are working on refining the device for use in OccluRad embolization microsphere preclinical trials, scheduled in early 2015. Enginuity will also undertake additional development and refinement on the ancillary delivery device for the first round of human testing, preparing for a full commercial launch for the product.
“We’re working hard to get the relevant regulatory approvals in place for Enginuity to provide value to ABK and the many other med tech players blossoming in the Maritimes” adds Ben Garvey, CEO of Enginuity Inc, based on Herring Cove Road in Halifax.
Dr Bob Abraham, ABK’s Chief Executive Officer sees the relationship as key to the successful launch of OccluRad embolization microspheres, adding “Enginuity have the right mix of skills, concise processes and personality to make the difference moving forwards.”
HALIFAX, Canada; October 15, 2014 - ABK Biomedical Inc., announced today the appointment of three leading experts in interventional radiology to its Clinical Advisory Board: Dr. Scott Goodwin, Dr. Jim Spies and Dr. Bob Lewandowski.
"We are thrilled to have these pioneers in uterine fibroid embolization and interventional oncology on our team of clinical advisors," said Dr. Bob Abraham, chief executive officer of ABK Biomedical. “The experience of these world leaders is going to be invaluable as we move OccluRad embolization microspheres into clinical trials and continue to expand our pipeline of novel radiopaque embolic therapies.”
Dr. Scott Goodwin, incoming Chair of ABK Biomedical’s clinical advisory board stated, “Minimally invasive, image-guided embolic therapies are becoming the patient's first choice for treatment of their uterine fibroids. ABK Biomedical’s innovations in this area makes this a very exciting opportunity to guide their efforts, together with the expertise of Dr. Spies and Dr. Lewandowski.”
Dr. Goodwin is an interventional radiologist, best known for introducing uterine artery embolization for the treatment of uterine fibroids (UAE) in North America. He is Chief of Radiology at UC Irvine Medical Center and also performs chemoembolization for liver cancer. Dr. Goodwin is the Hasso Brothers Chair of the Department of Radiological Sciences at University of California, Irvine Medical School. He has repeatedly been listed among the nation's Best Doctors in America® for Radiology, and is regarded as one of the top 10 researchers in uterine fibroids. Dr. Goodwin completed his M.D. at Harvard University, internship at Washington University, followed by his residency and fellowship at UCLA.
Dr. Jim Spies leads the Georgetown Uterine Fibroid Embolization Program, one of the largest and most experienced in the United States. Dr. Spies has been a principal investigator in five funded research trials, including the FIBROID Registry, a study of 3,000 women. He is Chair of the Radiology Department at MedStar Georgetown University hospital, Professor of Radiology at Georgetown University Medical Center and has published extensively on uterine artery embolization. He completed his M.D. at Georgetown University, residency at University of California, San Francisco, and fellowship in interventional radiology at New York University.
Dr. Bob Lewandowski is an Associate Professor of Radiology and Director of Interventional Oncology at the Northwestern University Feinberg School of Medicine in Chicago. He has published extensively on chemoembolization and radioembolization to treat liver cancer and is a world authority in interventional radio-oncology. A leading researcher, Dr. Lewandowski is involved with both pre-clinical and clinical studies in Interventional Oncology. Dr. Lewandowski received his M.D. from Michigan State University, completed residency at William Beaumont Hospital and his fellowship at Northwestern Hospital.
ABK Biomedical Inc. is pursuing validation, production and sale of OccluRad embolization microspheres, ABK's lead radiopaque embolic product, as it develops additional therapies for chemoembolization and radioembolization. While still investigational, ABK’s innovative radiopaque embolic therapies have the potential to provide simpler, safer and more cost effective solutions for treating hypervascular tumors and diseases.
HALIFAX, Canada; October 2, 2014 – ABK Biomedical Inc.,announced today it is consolidating its operations to Halifax. Heading up this consolidation will be ABK Biomedical’s new Chief Executive Officer, Dr. Bob Abraham. As an ABK Biomedical co-founder, Dr. Abraham also serves as Chief Medical Officer and is a member of its Board of Directors.
The company focus to Halifax and CEO appointment follow ABK Biomedical’s recent award of $2.14M from Atlantic Canada Opportunities Agency (ACOA), under the Atlantic Innovation Fund (AIF). The AIF award will enable ABK to simplify and enhance chemotherapy and radiotherapy for cancer patients with ABK’s novel radiopaque embolic beads. In addition to ACOA’s support, ABK has received funding through strong local, national and US based angel and institutional investment. The commitment of the private investors, with the leverage from AIF funding will fuel ABK’s lead product first-in-human trials as well as advancing a robust pipeline of products.
In his new CEO role, Dr. Abraham will steer ABK’s lead product OccluSystem through clinical validation, regulatory approval and market readiness. Dr. Abraham will also lead the expansion of the company’s product pipeline as ABK Biomedical looks to develop next generation resorbable, radiopaque, drug eluting and radioembolic agents to be used for chemoembolization and radioembolization treatment of liver cancer.
“As a nationally recognized embolization expert, we are delighted to have Dr. Abraham as our new, full-time CEO,” said Dr. Aaron Berez, chairman of the board of ABK Biomedical. “His experience as a clinician, entrepreneur and med tech investor as well as his dedication to patients and passion for innovation make him the ideal candidate to lead ABK Biomedical.”
“Having the full ABK Biomedical team, including product engineering, quality management system (QMS), regulatory, and R&D, together in our Halifax facilities supports our commitment to bringing our novel embolic systems to patients as quickly as possible,” said CEO Dr. Bob Abraham.
Dr. Abraham has spent more than 20 years as a practicing clinician and interventional radiologist at Capital Health (CDHA). He has successfully licensed catheter innovations and established the Uterine Fibroid Embolization (UFE) program at QEII Health Sciences Centre and IWK in 2001. Dr. Abraham earned his medical degree from Dalhousie University in Halifax, interned at St. Paul’s Hospital in Vancouver, returned to complete specialty training in Diagnostic Imaging at Dalhousie University and then completed subspecialty training in Interventional Radiology at the Royal Melbourne Hospital in Australia. He is a Fellow of the Royal College of Physicians and Surgeons of Canada (FRCPC) and just completed his tenure as Chair for the Royal College's exam in Diagnostic Radiology. He is currently President-Elect for the Canadian Association of Radiologists (CIRA) and will assume the role of President in June 2015.
Founded in 2012, ABK Biomedical Inc. is pursuing development, production and sale of embolic agents and peripheral vascular delivery devices. The company’s radiopaque OccluSystem and pipeline products, while still investigational, have the potential to provide simpler, safer and more cost effective solutions for treating hypervascular tumors and diseases.